Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Pramipexole + Ondansetron (CTC-501) in MDD
NCT03642964Phase 2Active, not recruiting
- Sponsor
- Chase Therapeutics
- Start
- Sep 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pramipexole in major depressive disorder (MDD), sponsored by Chase Therapeutics. Started Sep 2018; status: active, not recruiting.
02
Drugs
pramipexole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03642964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03642964.